Mkt Cap $494M
52-Week Range
Breeze Holdings Acquisition Corp.
Most recently: Current Report on Form 6-K (2026-02-26).
$494M
Market Cap
—
Revenue
-$62M
Net Income
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.